Landmark trial
Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial
Mulvenna P, Nankivell M, Barton R, et al. · MRC Clinical Trials Unit
DoseLab summary
Phase 3 non-inferiority trial (QUARTZ) in non-small cell lung cancer with brain metastases unsuitable for surgery or SRS: adding whole-brain radiotherapy, 20 Gy in 5 fractions, to supportive care gave little additional benefit. Citation checked against Crossref.
Why this is useful
Why whole-brain treatment is not offered to every patient with poor-prognosis brain metastases.
Reference details
- Title
- Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial
- Authors / organization
- Mulvenna P, Nankivell M, Barton R, et al. · MRC Clinical Trials Unit
- Publication / protocol
- Lancet. 2016;388(10055):2004–2014
- Version
- Pending verification
- Year
- 2016
- DOI
- 10.1016/S0140-6736(16)30825-X
- Disease sites
- CNS / Brain
- Topics
- Whole brain, Palliative, Brain metastases, Landmark trial
- Fractionation context
- 20 Gy / 5 fx
- Last reviewed by DoseLab
- Pending verification